Varmus panel to study patent constraints

June 1997
Nature;6/12/1997, Vol. 387 Issue 6634, p646
Academic Journal
Announces an expert panel set up by Harold Varmus, the director of the US National Institutes of Health, to explore ways of easing restrictions on access to propietary materials and methods by research scientists. Rebecca Eisenberg, law professor and intellectual property expert at the University of Michigan as leader of the committee.


Related Articles

  • Higher status for `research risks' office? Wadman, Meredith // Nature;2/18/1999, Vol. 397 Issue 6720, p550 

    Focuses on the scheduled delivery of a report on the future of the Office for Protection from Research Risks to Harold Varmus, the director of the National Institutes of Health (NIH). Question of whether the office should remain in the NIH or be elevated to the office of the secretary of the...

  • Varmus strikes `reasonable pricing' clause in CRADAs. Jenks, Susan // JNCI: Journal of the National Cancer Institute;5/3/95, Vol. 87 Issue 9, p642 

    Reports that National Institutes of Health (NIH) Director Harold Varmus, has determined the `reasonable pricing' clause to be unreasonable, and has removed it from Cooperative Research and Development Agreements between federal laboratories and private industry. Belief that the clause would...

  • Varmus nominated to head NIH. Greene, Susan // Nature;8/12/1993, Vol. 364 Issue 6438, p567 

    Reports on the nomination of Harold Varmus of the University of California, San Francisco (UCSF) as director of the U.S. National Institutes of Health (NIH). Varmus' Nobel prize; Tasks as NIH director; Personal comments; Credentials; Lobbying efforts with the government; Positions to be...

  • Varmus reassuring for NIH.  // Nature;8/12/1993, Vol. 364 Issue 6438, p561 

    Opinion. Welcomes the nomination of Harold Varmus as director of the National Institutes of Health (NIH) by U.S. President Bill Clinton. Nomination as a sign that Clinton put science above politics; Choice of candidates under Bush and Reagan administrations; NIH under Bernadine Healy; Varmus'...

  • Varmus deft with Senate on NIH strategy. Culliton, Barbara J. // Nature;11/11/1993, Vol. 366 Issue 6451, p99 

    Reports on the appearance of Harold Varmus, director-designate of the United States National Institutes of Health for confirmation hearings before the Senate. Accomplishments of Varmus cited by members of the Senate Committee on Labor and Human Resources; Question on the treatment of an unusual...

  • Varmus speaks out on need to boost clinical research. Gavaghan, Helen // Nature;11/10/1994, Vol. 372 Issue 6502, p118 

    Reports that Harold Varmus, director of the US National Institutes of Health has asked the American Association of Medical Colleges to suggest an ombudsman to help resolve the crisis confidence in clinical research. Identification of problem areas in clinical research in the United States;...

  • NIH scientists pressed to maintain standards. Macilwain, Colin // Nature;5/12/1994, Vol. 369 Issue 6476, p91 

    Reports on the proposed reforms reported by a panel set up by Congress regarding the maintenance of standards of the United States National Institutes of Health (NIH). Proposals under the reform; Plans of NIH director Harold Varmus for using the reforms to impose consistent standards; Reason...

  • Gene therapy group faces uncertain future. Jenks, Susan // JNCI: Journal of the National Cancer Institute;11/6/96, Vol. 88 Issue 21, p1523 

    Relates the plans of National Institutes of Health director Harold Varmus to revise the gene therapy policies of the agency. Protocols for germline corrections for genetic disease; Possible dismantling of the Recombinant DNA Advisory Committee (RAC); Reaction of oppositionists to RAC dismantling.

  • A word to Varmus. Pryor, David; Hatfield, Mark // Hastings Center Report;Jul/Aug96, Vol. 26 Issue 4, p46 

    Presents a letter from legislators to National Institutes of Health director Harold Varmus expressing concerns for the proposed abolition of the Recombitant DNA Advisory Committee (RAC). Calls for reconsideration in disbanding the RAC; Policy issues on the RAC's role in genetics research.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics